Your browser doesn't support javascript.
loading
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells.
Bao, Erik L; Nandakumar, Satish K; Liao, Xiaotian; Bick, Alexander G; Karjalainen, Juha; Tabaka, Marcin; Gan, Olga I; Havulinna, Aki S; Kiiskinen, Tuomo T J; Lareau, Caleb A; de Lapuente Portilla, Aitzkoa L; Li, Bo; Emdin, Connor; Codd, Veryan; Nelson, Christopher P; Walker, Christopher J; Churchhouse, Claire; de la Chapelle, Albert; Klein, Daryl E; Nilsson, Björn; Wilson, Peter W F; Cho, Kelly; Pyarajan, Saiju; Gaziano, J Michael; Samani, Nilesh J; Regev, Aviv; Palotie, Aarno; Neale, Benjamin M; Dick, John E; Natarajan, Pradeep; O'Donnell, Christopher J; Daly, Mark J; Milyavsky, Michael; Kathiresan, Sekar; Sankaran, Vijay G.
Afiliação
  • Bao EL; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Nandakumar SK; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Liao X; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Bick AG; Harvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, MA, USA.
  • Karjalainen J; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Tabaka M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gan OI; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Havulinna AS; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kiiskinen TTJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lareau CA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • de Lapuente Portilla AL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Li B; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Emdin C; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Codd V; VA Boston Healthcare, Section of Cardiology, Boston, MA, USA.
  • Nelson CP; Harvard Medical School, Boston, MA, USA.
  • Walker CJ; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Churchhouse C; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • de la Chapelle A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Klein DE; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Nilsson B; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Wilson PWF; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Cho K; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Pyarajan S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gaziano JM; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Samani NJ; Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, USA.
  • Regev A; Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
  • Palotie A; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Neale BM; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Dick JE; Department of Cardiovascular Sciences, Glenfield Hospital, Leicester, UK.
  • Natarajan P; National Institute for Health Research (NIHR) Leicester Biomedical Centre, Glenfield Hospital, Leicester, UK.
  • O'Donnell CJ; Department of Cardiovascular Sciences, Glenfield Hospital, Leicester, UK.
  • Daly MJ; National Institute for Health Research (NIHR) Leicester Biomedical Centre, Glenfield Hospital, Leicester, UK.
  • Milyavsky M; Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Kathiresan S; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Sankaran VG; Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Nature ; 586(7831): 769-775, 2020 10.
Article em En | MEDLINE | ID: mdl-33057200
ABSTRACT
Myeloproliferative neoplasms (MPNs) are blood cancers that are characterized by the excessive production of mature myeloid cells and arise from the acquisition of somatic driver mutations in haematopoietic stem cells (HSCs). Epidemiological studies indicate a substantial heritable component of MPNs that is among the highest known for cancers1. However, only a limited number of genetic risk loci have been identified, and the underlying biological mechanisms that lead to the acquisition of MPNs remain unclear. Here, by conducting a large-scale genome-wide association study (3,797 cases and 1,152,977 controls), we identify 17 MPN risk loci (P < 5.0 × 10-8), 7 of which have not been previously reported. We find that there is a shared genetic architecture between MPN risk and several haematopoietic traits from distinct lineages; that there is an enrichment for MPN risk variants within accessible chromatin of HSCs; and that increased MPN risk is associated with longer telomere length in leukocytes and other clonal haematopoietic states-collectively suggesting that MPN risk is associated with the function and self-renewal of HSCs. We use gene mapping to identify modulators of HSC biology linked to MPN risk, and show through targeted variant-to-function assays that CHEK2 and GFI1B have roles in altering the function of HSCs to confer disease risk. Overall, our results reveal a previously unappreciated mechanism for inherited MPN risk through the modulation of HSC function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Hematopoéticas / Predisposição Genética para Doença / Transtornos Mieloproliferativos / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Hematopoéticas / Predisposição Genética para Doença / Transtornos Mieloproliferativos / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos